Clinical Trial

Randomised Evaluation of COVID-19 Therapy

Study acronym: RECOVERY
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
RECOVERY is a randomised trial of treatments to prevent death in patients hospitalised with pneumonia. The treatments being investigated are: COVID-19: Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Colchicine, IV Immunoglobulin (children only), Convalescent plasma, Casirivimab+Imdevimab, Tocilizumab, Aspirin, Baricitinib, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid or Anakinra (children only) Influenza: Baloxavir marboxil, Oseltamivir, Corticosteroids (dexamethasone) Community-acquired pneumonia: Corticosteroids (dexamethasone)
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2020-05-07; most recent amendment 2026-04-15.
Trial Details
NCT Number NCT04381936
Lead Sponsor University of Oxford
Collaborators: UK Research and Innovation, National Institute for Health Research, United Kingdom, Wellcome Trust, Bill and Melinda Gates Foundation, Department for International Development, United Kingdom, Health Data Research UK, Medical Research Council Population Health Research Unit, NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Flu Lab
Conditions Pneumonia
Enrollment 70,000 participants
Start Date 2020-03-19
Primary Completion 2028-09-30 (estimated)
Study Completion 2038-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-21